Lee's Pharm to Market Solasia's Oral Mucositis Treatment in China

Lee’s Pharm acquired Greater China commercialization rights to episil ® , a treatment for oral mucositis, from Japan's Solasia Pharma. The agreement does not include Taiwan nor the cities of Beijing, Shanghai or Guangzhou, which Solasia will retain. episil ® , an oral liquid that treats the pain associated with oral mucositis, was developed by Camurus of Sweden. Solasia in-licensed rights to the product for Japan and China in 2015. Financial details of the agreement were not disclosed. More details.... Stock Symbol: (HK: 0950) Share this with colleagues: // //